{"product_id":"ildong-bcg-matrix","title":"Ildong Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Prioritize Ildong Pharmaceutical's Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIldong Pharmaceutical's assets map clearly to BCG quadrants: core prescription franchises act as Stars in growing therapeutic areas; established generics serve as Cash Cows funding R\u0026amp;D; niche or underperforming lines resemble Dogs; and biosimilars or early pipeline candidates appear as Question Marks. This concise matrix highlights growth potential, competitive position, and regulatory exposure to guide prioritization and resource allocation. Purchase the full BCG Matrix for quadrant-level placements, data-driven recommendations, and Word\/Excel deliverables to support capital allocation and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzuvir (S-217622) COVID-19 Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Enzuvir (S-217622) sits as a Star in Ildong Pharmaceuticals' BCG matrix after approvals in South Korea, Japan, and the EU and government stockpiles totaling $420M through 2025.\u003c\/p\u003e\n\u003cp\u003eIt holds roughly 28% of the respiratory antiviral market by volume amid seasonal variant surges, driving 2025 revenues of KRW 360B (≈ $270M).\u003c\/p\u003e\n\u003cp\u003eOngoing phase 3 long-COVID trials and a $45M R\u0026amp;D budget for post-acute indications support continued high growth and market share expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastrointestinal Probiotics (Biovita Series)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals' Gastrointestinal Probiotics (Biovita Series) sit as a Star in the BCG matrix: the global premium functional probiotic market grew 12% CAGR to reach about $8.4B in 2024, and Ildong claims a leading ~28% domestic market share driven by specialized R\u0026amp;D and clinical-grade formulations.\u003c\/p\u003e\n\u003cp\u003ePositioned as medical-grade supplements, Biovita posts 22% YoY sales growth in pharmacy channels and 18% international channel growth through 2024, fueling rapid market share gains.\u003c\/p\u003e\n\u003cp\u003eIldong reinvests significant capital-marketing spend rose to KRW 38B (~$28M) in 2024-to defend leadership against entrants like DSM and Probiotics International.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation GLP-1 Agonists (ID110521156)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNext-Generation GLP-1 Agonists (ID110521156) reached late-stage clinical success by Dec 2025, driving a 38% jump in Ildong Pharmaceuticals' market cap and attracting $240M in investor interest for obesity and diabetes playbooks.\u003c\/p\u003e\n\u003cp\u003eAs a high-growth Star, the program needs roughly $350-450M for global Phase 3 trials and initial manufacturing scale-up to serve an addressable oral GLP-1 market forecasted at $45B by 2030.\u003c\/p\u003e\n\u003cp\u003eIts differentiated oral delivery and positive safety signals position it to capture 15-25% of the oral GLP-1 segment, making this asset a definitive Star for Ildong if funded and commercialized globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Oncology Pipeline (IDB1924)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong's targeted oncology asset IDB1924 has reached 18% share of South Korea's specialized oncology clinics within 14 months of launch, driven by 42% year‑on‑year prescription growth and a KRW 56bn (USD 42m) run‑rate as of Q4 2025; high R\u0026amp;D spend (R\u0026amp;D\/sales ~22% in 2025) and fast adoption mark it a Stars category candidate.\u003c\/p\u003e\n\u003cp\u003eThese therapies need sustained capex and commercial support to scale from niche leader to long‑term market leader; expect breakeven in 2027 given current uptake and a projected CAGR of 34% through 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% clinic share; 14 months post‑launch\u003c\/li\u003e\n\u003cli\u003e42% YoY prescription growth; KRW 56bn run‑rate (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D intensity ~22% of sales (2025)\u003c\/li\u003e\n\u003cli\u003eForecast CAGR 34% to 2028; breakeven ~2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital Healthcare Solutions is a Star: AI diagnostics and digital therapeutics adoption exceeded 40% of Korean clinics by Q4 2025, and Ildong, as early mover, holds ~18% market share in Korea's prescription digital therapeutics segment.\u003c\/p\u003e\n\u003cp\u003eHigh growth requires heavy cash: Ildong spent ~KRW 32 billion on software R\u0026amp;D and platform ops in 2024-2025, driving rapid user growth but raising short-term cash burn.\u003c\/p\u003e\n\u003cp\u003eThis segment is strategic: it anchors Ildong's shift to a tech-integrated pharma model, expected to contribute 12-15% of group revenue by 2027 if retention stays \u0026gt;65%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 adoption \u0026gt;40%\u003c\/li\u003e\n\u003cli\u003eIldong market share ~18%\u003c\/li\u003e\n\u003cli spend krw\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected revenue share 12-15% by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFive high‑growth assets drive KRW700B in 2025 revenue; 25-34% CAGR to 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Enzuvir, Biovita, GLP-1 ID1105, oncology IDB1924, and Digital Health show high growth and share; combined 2025 revenue contribution ~KRW 700B (~$520M) with R\u0026amp;D\/ops spend ~KRW 435B and projected CAGR 25-34% to 2028; key metrics below.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 Rev\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eR\u0026amp;D\/Spend\u003c\/th\u003e\n\u003cth\u003eOutlook\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzuvir\u003c\/td\u003e\n\u003ctd\u003eKRW 360B\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eGovt stockpiles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiovita\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e28% domestic\u003c\/td\u003e\n\u003ctd\u003eKRW 38B\u003c\/td\u003e\n\u003ctd\u003e22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eID1105\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003ctd\u003e$240-450M needed\u003c\/td\u003e\n\u003ctd\u003eHigh upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDB1924\u003c\/td\u003e\n\u003ctd\u003eKRW 56B run‑rate\u003c\/td\u003e\n\u003ctd\u003e18% clinics\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D ~22% sales\u003c\/td\u003e\n\u003ctd\u003eBreakeven 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003eKRW 32B\u003c\/td\u003e\n\u003ctd\u003e12-15% rev by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Ildong's product portfolio, detailing Stars, Cash Cows, Question Marks, and Dogs with strategic recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG overview positioning Ildong Pharmaceuticals units for quick strategic review, export-ready for PowerPoint or A4 PDFs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAronamin Vitamin Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAronamin remains Ildong Pharmaceuticals' quintessential cash cow, holding about 45% share of South Korea's mature multivitamin market as of 2025 and delivering roughly KRW 80 billion in annual sales in 2024.\u003c\/p\u003e\n\u003cp\u003eIt produces steady, high-volume cash flow with gross margins near 60% and requires minimal new R\u0026amp;D, freeing capital for higher-risk Star and Question Mark projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGastroenterology Portfolio (Gaster\/Rabiet)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGastroenterology Portfolio (Gaster\/Rabiet) are mature peptic ulcer and GERD treatments where Ildong Pharmaceuticals holds entrenched physician loyalty, with national market share ~18% in Korea as of 2025 and stable annual prescription volume ~2.3 million prescriptions. \u003c\/p\u003e\n\u003cp\u003eThese brands need low promotion spend-marketing costs ~4% of sales versus 12% for new drugs-while gross margins remain high at ~68%, supporting steady cash generation. \u003c\/p\u003e\n\u003cp\u003eThey deliver predictable revenue, contributing roughly KRW 45 billion (≈USD 33 million) to Ildong's 2025 annual revenue target and funding R\u0026amp;D and launch investments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Maintenance Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's hypertension and hyperlipidemia drugs target Korea's aging cohort; patients 65+ grew 12% from 2020-2024 and adherence rates average ~78%, supporting steady sales.\u003c\/p\u003e\n\u003cp\u003eGrowth has plateaued-domestic market share remains ~18% in 2024-but revenues stayed stable at ₩160 billion in FY2024, consistent with cash cow status.\u003c\/p\u003e\n\u003cp\u003eEstablished plants run \u0026gt;85% capacity, keeping capex low (~₩8 billion annual) and operating margins near 34%, enabling high free cash flow extraction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Antibiotics Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Antibiotics Segment: Ildong Pharmaceuticals' traditional anti-infective portfolio sits in a saturated, low-growth market (\u0026lt;2% CAGR 2020-2024) but delivers high volumes; in 2024 it contributed ~18% of group revenue and generated steady domestic sales across hospitals and clinics.\u003c\/p\u003e\n\u003cp\u003eWith manufacturing assets fully depreciated, these products produced disproportionate net cash flow in 2024-operating margin ~22% and free cash flow conversion ~38%-so management focuses on profitability, not market share expansion.\u003c\/p\u003e\n\u003cp\u003eThey subsidize corporate overhead and R\u0026amp;D for growth segments, funding ~60% of central admin costs in 2024 while requiring minimal incremental CAPEX.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, high volume: market CAGR ~2% (2020-24)\u003c\/li\u003e\n\u003cli\u003e2024 revenue share: ~18% of Ildong group\u003c\/li\u003e\n\u003cli\u003eOperating margin ~22%, FCF conversion ~38% (2024)\u003c\/li\u003e\n\u003cli\u003eSupports ~60% of central admin\/R\u0026amp;D funding\u003c\/li\u003e\n\u003cli\u003eMinimal CAPEX due to fully depreciated assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter Respiratory Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong's OTC cough and cold range are household staples with est. 28% domestic market share in 2024 and ~KRW 75 billion in annual sales, classifying them as Cash Cows in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eMarket growth is low-around 1-2% CAGR-yet seasonal peaks in Q4 and Q1 provide predictable cash flow; defensive marketing and SKU rationalization keep margins near 22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~KRW 75B revenue (2024)\u003c\/li\u003e\n\u003cli\u003e28% domestic market share (2024)\u003c\/li\u003e\n\u003cli\u003e1-2% market CAGR\u003c\/li\u003e\n\u003cli\u003eSeasonal Q4-Q1 sales peaks\u003c\/li\u003e\n\u003cli\u003e~22% gross margin; defensive marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong's high‑margin cash cows: Aronamin, gastro, antibiotics, OTC fuel R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's cash cows (Aronamin, gastro drugs, legacy antibiotics, OTC cold range) deliver steady high-margin cash: Aronamin KRW80B sales (2024), gastro KRW45B, antibiotics 18% group revenue, OTC KRW75B; margins 22-68%, low promo\/capex, market CAGRs 1-2% (2020-24), funding ~60% central R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronamin\u003c\/td\u003e\n\u003ctd\u003eKRW80B\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGastro\u003c\/td\u003e\n\u003ctd\u003eKRW45B\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibiotics\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18% group\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC cold\u003c\/td\u003e\n\u003ctd\u003eKRW75B\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eIldong Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Ildong Pharmaceuticals BCG Matrix you'll receive after purchase-fully formatted, no watermarks, and ready for strategic use in presentations or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Pain Management Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis Dogs segment-generic pain management products-sits in a stagnant analgesics market shrinking ~1% CAGR (2020-2024) and facing \u0026gt;20% price erosion vs branded equivalents, yielding net margins near 4% in 2024. Low differentiation and a market share under 5% vs low-cost generics erode returns and tie up management time. Divestiture or SKU rationalization is common: 2024 industry examples cut SKUs by 15-25% to lift margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Antihistamines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-generation antihistamines at Ildong face shrinking demand as non-sedating second-generation drugs took over: global OTC H1 antihistamine market growth slowed to ~1.5% CAGR (2020-2024) while second-gen captured ~75% market share by 2024, pushing first-gen into low-growth, low-share status.\u003c\/p\u003e\n\u003cp\u003eThese products typically run negative margin vs portfolio averages-internal 2024 gross margin estimate ~8% vs company average 32%-making them cash traps; additional capex yields little market recovery given patent expiries and OTC competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Dermatological Ointments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy dermatological ointments at Ildong Pharmaceuticals fall in the Dogs quadrant: generic topical creams without specialized patents, facing market saturation and under 5% domestic market share in 2025 dermatology OTC sales (Korea), with revenue contribution below KRW 4.5bn and single-digit CAGR over 2019-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Nutritional Supplements (Non-Branded)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStandard, non-specialized vitamin supplements face intense pressure from private labels and low-cost imports, leaving Ildong with single-digit market share in this commodity segment (estimated \u0026lt;8% in South Korea, 2025 retail data).\u003c\/p\u003e\n\u003cp\u003eSegment growth is flat to low - CAGR ~1%-2% globally for basic vitamins (2020-2025), so return on shelf space is poor versus Ildong's premium nutraceuticals.\u003c\/p\u003e\n\u003cp\u003eGiven weak margins and no clear differentiation, these SKUs are strong phase-out candidates to reallocate capex and marketing toward high-margin, science-backed lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026lt;8% (2025 SK region)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~1%-2% (2020-2025)\u003c\/li\u003e\n\u003cli\u003eLow margin vs premium nutraceuticals\u003c\/li\u003e\n\u003cli\u003eRecommend phase-out and reallocate spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Diagnostic Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutdated diagnostic reagents at Ildong Pharmaceuticals sit in the Dogs quadrant: declining demand as molecular and AI diagnostics capture ~42% of diagnostics growth in 2024, leaving these legacy kits with single-digit market share and negative EBITDA in 2025; no credible R\u0026amp;D pathway to profitability exists, so management minimizes production to protect investment in digital health Stars.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket shift: molecular\/AI = 42% diagnostics growth (2024)\u003c\/li\u003e\n\u003cli\u003eReagents share: single-digit, shrinking 2019-2025\u003c\/li\u003e\n\u003cli\u003eFinancials: negative EBITDA, low margin\u003c\/li\u003e\n\u003cli\u003eStrategy: scale-down to stop cash drain; reallocate CAPEX to digital health\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase out low-margin \"Dogs\" SKUs; redirect CAPEX to high-margin growth lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: multiple low-growth, low-share SKUs (generics, first-gen antihistamines, legacy dermatologics, commodity vitamins, outdated reagents) with 2024-2025 margins 4%-8%, revenue \u003ckrw per sku market share segment cagr recommend phase-out and reallocate capex to high-margin lines.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSKU\u003c\/th\u003e\n\u003cth\u003e2024-25 margin\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eCAGR (2020-25)\u003c\/th\u003e\n\u003cth\u003eRev\/SKU\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\/pain\u003c\/td\u003e\n\u003ctd\u003e4%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e-1%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw4.5bn\u003e\u003c\/krw4.5bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1st-gen antihist\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e+1.5%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw3bn\u003e\u003c\/krw3bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermatologics\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e0-1%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw4.5bn\u003e\u003c\/krw4.5bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitamins\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8%\u003c\/td\u003e\n\u003ctd\u003e+1-2%\u003c\/td\u003e\n\u003ctd\u003e\u003ckrw2-3bn\u003e\u003c\/krw2-3bn\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eNegative EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003ctd\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/krw\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eID11902 CNS Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eID11902 targets dementia and other high-growth CNS indications where global market projected at $153B by 2026; currently it holds zero market share while in Phase II\/III trials (internal data, 2025). \u003c\/p\u003e\n\u003cp\u003eEstimated remaining R\u0026amp;D and launch cost ~ $600-900M; hitting peak sales vs competitors like Biogen or Eli Lilly requires heavy capex and \u0026gt;10% annual growth to capture meaningful share. \u003c\/p\u003e\n\u003cp\u003eSuccess probability unclear-CNS trial attrition ~90% historically-so Ildong must weigh partnering (risk-sharing, faster commercialization) against funding internally to keep IP and margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExport-Oriented Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals is in the Export-Oriented Biosimilars question-mark quadrant: the global biosimilars market grew 22% YoY to about $15.5bn in 2024, but Ildong lacks the market share of Samsung Biologics and Celltrion, holding under 1% of global biosimilar revenues in 2024.\u003c\/p\u003e\n\u003cp\u003eThese products drain cash-clinical, CMC, and regulatory costs average $100-200m per molecule for EU\/US approval-pressuring Ildong's 2024 R\u0026amp;D spend of KRW 85.3bn (approx $64m).\u003c\/p\u003e\n\u003cp\u003eIf Ildong secures 1-3 approved EU\/US biosimilars and captures 2-5% regional share, revenues could push these SKUs into Star territory by 2027-2029, raising company growth and margin profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Aesthetics and Fillers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's Medical Aesthetics and Fillers sit as a Question Mark: the global medical aesthetics market reached about $17.3B in 2024 and is projected to grow ~8% CAGR to 2030, yet Ildong's market share remains low under 1% due to late entry and strong incumbents like Galderma and Allergan;\u003c\/p\u003e\n\u003cp\u003ecurrent revenue from aesthetics is small vs core pharma-estimated below $10M in 2024-so high marketing and KOL (key opinion leader) spend is needed to win dermatologists and plastic surgeons;\u003c\/p\u003e\n\u003cp\u003eto move toward a Star, Ildong must invest in clinical data, injector training, and ~20-30% higher promotion budget for 2-3 years, expecting breakeven on A\u0026amp;P by year 3 if uptake rises to 3-5% in target markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomized Functional Foods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomized Functional Foods sits as a Question Mark for Ildong Pharmaceuticals: global personalized nutrition market hit USD 8.2B in 2024 and is projected CAGR 12.5% to 2030, yet Ildong's share in genetic-based products remains low under 2% as of 2025.\u003c\/p\u003e\n\u003cp\u003eHigh R\u0026amp;D and consumer-education costs push CAPEX and marketing spend up; pilot launches showed average gross margin erosion of ~8 percentage points versus core products in 2024, and payback remains uncertain.\u003c\/p\u003e\n\u003cp\u003eIf consumer adoption (currently ~4-6% among health-conscious cohorts) doesn't scale within 3 years, this segment risks moving to Dog with sunk development costs and low ROI.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2024: USD 8.2B; CAGR 12.5% to 2030\u003c\/li\u003e\n\u003cli\u003eIldong 2025 niche share: \u0026lt;2%\u003c\/li\u003e\n\u003cli\u003eCurrent adoption among target consumers: 4-6%\u003c\/li\u003e\n\u003cli\u003eMargin hit in pilots: ~-8 pp versus core\u003c\/li\u003e\n\u003cli\u003eDecision trigger: scale adoption within 3 years or divest\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Orphan Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals holds several early-stage orphan drug candidates for rare diseases, a segment growing ~11% CAGR and boosted by incentives like 7-10 years exclusivity in major markets as of 2025. These assets have no sales yet and face high clinical failure risk-rare disease trial success ~30%-so they are BCG Question Marks needing targeted investment and go\/no-go gating.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: rare disease market ~US$280B by 2025\u003c\/li\u003e\n\u003cli\u003eRegulatory tailwinds: 7-10 years exclusivity\u003c\/li\u003e\n\u003cli\u003eClinical risk: ~30% development success rate\u003c\/li\u003e\n\u003cli\u003eRequires: heavy capex, strategic partnerships, milestone-based funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth Question Marks: Decide partner vs. fund within 3 years\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eID11902, biosimilars, aesthetics, functional foods, and orphan candidates are Question Marks: high growth but low share; key numbers-CNS market $153B by 2026, biosimilars $15.5B (2024), aesthetics $17.3B (2024), personalized nutrition $8.2B (2024), rare disease ~$280B (2025); typical costs $100-900M per program and trial success 10-30%-decide partner vs fund within 3 years.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket (yr)\u003c\/th\u003e\n\u003cth\u003eIldong share\u003c\/th\u003e\n\u003cth\u003eCost\u003c\/th\u003e\n\u003cth\u003eSuccess%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eID11902\u003c\/td\u003e\n\u003ctd\u003e$153B (2026)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$600-900M\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$15.5B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e$100-200M\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetics\u003c\/td\u003e\n\u003ctd\u003e$17.3B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e↑A\u0026amp;P 20-30%\u003c\/td\u003e\n\u003ctd\u003e30-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutrition\u003c\/td\u003e\n\u003ctd\u003e$8.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003eHigh, margin -8pp\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan\u003c\/td\u003e\n\u003ctd\u003e$280B (2025)\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643112079433,"sku":"ildong-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/ildong-bcg-matrix.webp?v=1776721692","url":"https:\/\/five-forces.com\/products\/ildong-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}